Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Brodalumab superior to ustekinumab in phase III trial in moderate to severe plaque psoriasis

Nov. 12, 2014

Oral JAK1 inhibitor shows dose-dependent activity in phase II psoriasis trial

Nov. 10, 2014

LEO Pharma licenses Japan Tobacco's JTE-052 for dermatology applications

Nov. 7, 2014

Xoma opens enrollment in phase III study of gevokizumab for pyoderma gangrenosum

Nov. 7, 2014

EMA accepts Oleogel-S10 MAA for review

Nov. 5, 2014

Sodium thiosulfate designated orphan drug by the FDA

Nov. 3, 2014

Celgene to begin phase II study of PDA-002

Oct. 31, 2014

EMA recommends that Clinuvel's Scenesse be approved for EPP

Oct. 27, 2014

Clinical response maintained with long-term brodalumab therapy in patients with psoriasis

Oct. 23, 2014

TWi Biotechnology's AC-201 receives FDA orphan drug designation

Oct. 22, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...